DEFB1 represented a prognostic indicator of higher T stage (T3 and T4); thus, using its agonist or modulating its regulated pathway may improve the overall survival outcome of oral cancer patients with higher T stage, while such drug agents may be not meaningful for improving the prognosis in the OSCC patients with lower T stage. This evidence concerns the gene DEFB1 and lip and oral cavity carcinoma.